Product Information
NYSTATIN 100,000 UNIT/ML SUSP is a generic product labeled by PAI Holdings LLC, priced at $0.0569 per ML under NDC 00121086816. Its NADAC has been published 317 times since Sep 9, 2020.
FDA first approved this application on Jan 7, 2016. Its Orange Book therapeutic-equivalence code is AA.
Strength
100000 [USP'U]/mL
Manufacturer
PAI Holdings LLCNDC
00121086816
Classification
Generic
Dosage Form
SUSPENSION
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
NYSTATINApproval Type
Generic (ANDA)
FDA Application
ANDA203621FDA Approved
1/7/2016
TE Code
AA
On Market Since
7/17/2020
Pharmacological Classes
Price Statistics
The NADAC for NYSTATIN 100,000 UNIT/ML SUSP has been published 317 times since Sep 9, 2020, and over the history we have for it it has declined 17.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0569 per ML |
|---|---|
| All-time high | $0.0841 (Nov 11, 2020) |
| All-time low | $0.0373 (Sep 21, 2022) |
| 52-week high | $0.0652 |
| 52-week low | $0.0569 |
| Median price | $0.0565 |
| Average price | $0.0552 |
| Largest weekly change | +50.7% (Oct 21, 2020) |
| Weeks tracked | 317 |
| Tracking since | Sep 9, 2020 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 2% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
PAI Holdings LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
NYSTATIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Polyene Antifungal class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of NYSTATIN 100,000 UNIT/ML SUSP?
The current National Average Drug Acquisition Cost (NADAC) for NYSTATIN 100,000 UNIT/ML SUSP, manufactured by PAI Holdings LLC, is $0.0569 per ML (NDC 00121086816), effective Sep 30, 2026.
How has the price of NYSTATIN 100,000 UNIT/ML SUSP changed over time?
Over the history we have for it, the NADAC for NYSTATIN 100,000 UNIT/ML SUSP has declined 17.3%. It has been tracked across 317 weekly CMS publications since Sep 9, 2020.
What are the highest and lowest recorded NADAC prices for NYSTATIN 100,000 UNIT/ML SUSP?
Since Sep 9, 2020, the NADAC for NYSTATIN 100,000 UNIT/ML SUSP has ranged from a low of $0.0373 (Sep 21, 2022) to a high of $0.0841 (Nov 11, 2020), with a median of $0.0565 per ML.
Are there cheaper alternatives to NYSTATIN 100,000 UNIT/ML SUSP?
Yes. 4 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NYSTATIN 100,000 UNIT/ML SUSP, is $0.0561 per ML — about 2% below NYSTATIN 100,000 UNIT/ML SUSP.
Who manufactures NYSTATIN 100,000 UNIT/ML SUSP?
NYSTATIN 100,000 UNIT/ML SUSP (NDC 00121086816) is labeled by PAI Holdings LLC, and CMS classifies it as a generic product.